Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

62P - Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small cell lung cancer: Updated results from FOCUS-A study

Date

28 Mar 2025

Session

Poster Display session

Presenters

Baohui Han

Citation

Journal of Thoracic Oncology (2025) 20 (3): S1-S97. 10.1016/S1556-0864(25)00632-X

Authors

B. Han1, T. Chu1, G. Yu2, Z. Yu3, X. Wang4, J. Qian1

Author affiliations

  • 1 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 2 Shaoxing People's Hospital, Shaoxing/CN
  • 3 The Affiliated Hospital of Qingdao University, Qingdao/CN
  • 4 Qilu Hospital of Shandong University, Jinan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 62P

Background

Dual VEGF and EGFR blockade could delay emergence of EGFR TKI resistance and improve clinical outcomes in patients with EGFR-mutant NSCLC. This study was designed to explore the preliminary antitumor activity and safety of firmonertinib (a third-generation EGFR-TKI) combined with anlotinib (a multi-targeting TKI including anti-angiogenetic effects) in patients with treatment-naïve EGFR-mutant NSCLC.

Methods

FOCUS-A was a prospective multicenter phase II study. Forty patients with treatment-naïve, EGFR-mutant, locally advanced or metastatic NSCLC were enrolled. The regimen was firmonertinib (80 mg qd) plus anlotinib (10 mg qd, day 1 to 14 every 21 days). The primary endpoint was investigator-assessed objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included progression-free survival (PFS), Disease Control Rate (DCR), safety, etc.

Results

At data cut-off (6 Dec 2024), 40 eligible patients were enrolled with a median follow-up of 27.8 months. The median age was 63 years (range 40–71). Most patients were female (65%), never smoking (87.5%) and stage IV adenocarcinoma (95%). The ORR was 87.5% (95% CI, 73.2 to 95.8) and DCR was 100%. The median PFS was 25.1 months (95%CI, 17.9 to not reached). Among the 16 (40%) patients with baseline CNS metastases, the ORR was 87.5% (95%CI, 61.7 to 98.5) and DCR was 100%. The median PFS was 25.1 months (95%CI, 13.8 to 33.2). There was no difference in PFS between ex19del and ex21L858R mutations in patients with baseline CNS metastases (not reached vs 25.1 months; HR 0.72; 95%CI 0.18–2.92; p > 0.05). The median CNS PFS in these 16 patients was 33.2 months (95%CI, 17.9 to 33.2). Grade≥3 treatment-related adverse events (TRAE) were observed in 13 (32.5%) patients. The most common grade≥3 TRAEs were hypertension (7.5%) and proteinuria (7.5%).

Conclusions

Firmonertinib combined with anlotinib exhibited durable antitumor activity with tolerable and manageable safety profile in patients with treatment-naive EGFR-mutant NSCLC.

Clinical trial identification

NCT04895930.

Legal entity responsible for the study

The authors.

Funding

Shanghai Allist Pharmaceuticals.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.